Insights into the degradation of diphenhydramine - An emerging SARS-CoV-2 medicine by UV/Sulfite.

As Diphenhydramine (DPH) has been considered as a drug to treat SARS-CoV-2, the degradation of DPH from water was investigated and evaluated in this study by adopting an advanced oxidation/advanced reduction process - the UV/sulfite process. The UV/sulfite system was able to eliminate DPH within 6 mins under UV254nm and 1.0 mM sulfite. It was observed that the presence of N O 3 - , N O 2 - , C l - , H C O 3 - , and S O 4 2 - anions in water can affect the performance of UV/Sulfite degradation system. The mechanism of UV/sulfite/anions was evaluated which the presence of N O 3 - in UV/sulfite process has revealed faster initial decay rate but lower final DPH removal. It was observed that the UV/Sulfite process was extremely sensitive to pH as the dissociation of ion species varied among pH. The reaction became sluggish in acidic solution due to the dissociation of less reactive species such as HSO3 -. In alkaline solution, SO3 2- was the dominant species, producing powerful SO 3 ∙ - and e aq - when activated by UV at 254 nm. By conducting LC/MS analysis, the degradation pathway was proposed and can be summarized into four main pathways: hydroxylation, side chain cleavage, losing aromatic ring or ring opening. Scavenging tests were also carried out and validated the presence of various radicals contributing to the reaction, including e aq - , H˙, OH˙, SO3 ˙-, O2 •- and SO4 ˙-.

What We Are Learning from COVID-19 for Respiratory Protection: Contemporary and Emerging Issues.

Infectious respiratory diseases such as the current COVID-19 have caused public health crises and interfered with social activity. Given the complexity of these novel infectious diseases, their dynamic nature, along with rapid changes in social and occupational environments, technology, and means of interpersonal interaction, respiratory protective devices (RPDs) play a crucial role in controlling infection, particularly for viruses like SARS-CoV-2 that have a high transmission rate, strong viability, multiple infection routes and mechanisms, and emerging new variants that could reduce the efficacy of existing vaccines. Evidence of asymptomatic and pre-symptomatic transmissions further highlights the importance of a universal adoption of RPDs. RPDs have substantially improved over the past 100 years due to advances in technology, materials, and medical knowledge. However, several issues still need to be addressed such as engineering performance, comfort, testing standards, compliance monitoring, and regulations, especially considering the recent emergence of pathogens with novel transmission characteristics. In this review, we summarize existing knowledge and understanding on respiratory infectious diseases and their protection, discuss the emerging issues that influence the resulting protective and comfort performance of the RPDs, and provide insights in the identified knowledge gaps and future directions with diverse perspectives.